Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionOppenheimer Asset Management Inc.
Latest Disclosed Ownership2,405 shares
Latest Disclosed Value $ 1,858,200
Oppenheimer Asset Management Inc. reports 0.38% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 23, 2026 - Oppenheimer Asset Management Inc. filed a 13F-HR form disclosing ownership of 2,405 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $1,858,200 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 2,396 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 0.38% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,405 9 0.38 1,858 0.49 0.0053
2026-02-02 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,396 -32 -1.32 1,849 35.46 0.0227
2025-11-06 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,428 -180 -6.90 1,365 -0.29 0.0150
2025-07-31 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,608 643 32.72 1,369 9.87 0.0157
2025-04-23 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,965 1,965 1,246 0.0155
2024-02-13 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 0 -756 -100.00 0 -100.00
2023-11-08 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 756 22 3.00 622 18.03 0.0095
2023-08-03 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 734 15 2.09 527 -10.68 0.0078
2023-05-10 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 719 -62 -7.94 591 4.80 0.0091
2023-02-07 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 781 -216 -21.66 563 -18.05 0.0091
2022-11-14 2022-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 997 -59 -5.59 687 10.10 0.0121
2022-08-08 2022-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,056 98 10.23 624 -6.73 0.0105
2022-05-12 2022-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 958 -1,841 -65.77 669 -62.14 0.0095
2022-02-02 2021-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,799 -88 -3.05 1,767 1.20 0.0234
2021-11-12 2021-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,887 318 12.38 1,746 21.67 0.0248
2021-08-03 2021-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 2,569 222 9.46 1,435 29.16 0.0204
2021-05-17 2021-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 2,347 -23,363 -90.87 1,111 -91.06 0.0172
2021-02-11 2020-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 25,710 997 4.03 12,421 -10.21 0.2074
2020-11-13 2020-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 24,713 136 0.55 13,834 -9.75 0.2686
2020-08-11 2020-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 24,577 1,357 5.84 15,328 35.19 0.3163
2020-05-08 2020-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 23,220 22,739 4,727.44 11,338 6,164.09 0.2786
2020-02-07 2019-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 481 -30 -5.87 181 27.46 0.0038
2019-10-31 2019-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 511 -5 -0.97 142 -12.35 0.0032
2019-08-09 2019-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 516 -49 -8.67 162 -30.47 0.0036
2019-04-24 2019-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 565 -806 -58.79 233 -54.49 0.0052
2019-01-30 2018-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,371 -60 -4.19 512 -11.42 0.0127
2018-10-26 2018-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,431 128 9.82 578 28.73 0.0128
2018-08-10 2018-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,303 218 20.09 449 20.05 0.0110
2018-05-09 2018-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,085 -9,524 -89.77 374 -92.12 0.0094
2018-02-07 2017-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 10,609 0 0.00 4,745 0.00 0.1259
2017-11-14 2017-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 10,609 258 2.49 4,745 -6.67 0.1233
2017-08-09 2017-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 10,351 340 3.40 5,084 31.03 0.1405
2017-05-15 2017-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 10,011 10,011 3,880 0.1105
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.